Literature DB >> 12117842

Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy.

X Jouven1, A Hagege, P Charron, L Carrier, O Dubourg, J M Langlard, S Aliaga, J B Bouhour, K Schwartz, M Desnos, M Komajda.   

Abstract

BACKGROUND: QT abnormalities have been reported in left ventricular hypertrophy and hypertrophic cardiomyopathy.
OBJECTIVE: To determine the relation between left ventricular hypertrophy and increased QT interval in familial hypertrophic cardiomyopathy.
METHODS: The QT interval was measured in 206 genotyped adult subjects with familial hypertrophic cardiomyopathy from 15 unrelated families carrying mutations in the beta myosin heavy chain (beta-MHC) gene (five families, n = 68) or the cardiac myosin binding protein C (MyBPC) gene (10 families, n = 138). Subjects were classified as genetically unaffected (controls, n = 112), affected with left ventricular hypertrophy (penetrants, n = 58), or affected without left ventricular hypertrophy (non-penetrants, n = 36).
RESULTS: There was a significant increase in QTmax and QTmin from controls to non-penetrants and penetrants for both the MyBPC group (p < or = 0.001 and p < or = 0.001, respectively) and the beta-MHC group (p < or = 0.001 and p < or = 0.001, respectively). In the MyBPC group, the increase in the QT interval could be explained by increased left ventricular hypertrophy. In the beta-MHC group, non-penetrants had a significantly longer QTmax than controls despite the absence of left ventricular hypertrophy, and a similar QT interval to penetrants despite a lesser degree of left ventricular hypertrophy.
CONCLUSIONS: In familial hypertrophic cardiomyopathy, genetically affected subjects without left ventricular hypertrophy may have a prolonged QT duration, which depends not only on the degree of left ventricular hypertrophy, when present, but also on the causative mutation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117842      PMCID: PMC1767224          DOI: 10.1136/heart.88.2.153

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  32 in total

1.  Reproducibility and automatic measurement of QT dispersion.

Authors:  J M Glancy; P J Weston; H K Bhullar; C J Garratt; K L Woods; D P de Bono
Journal:  Eur Heart J       Date:  1996-07       Impact factor: 29.983

2.  Accuracy of four automatic QT measurement techniques in cardiac patients and healthy subjects.

Authors:  N B McLaughlin; R W Campbell; A Murray
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

3.  A point-score system for the ECG diagnosis of left ventricular hypertrophy.

Authors:  D W Romhilt; E H Estes
Journal:  Am Heart J       Date:  1968-06       Impact factor: 4.749

4.  Errors in manual measurement of QT intervals.

Authors:  A Murray; N B McLaughlin; J P Bourke; J C Doig; S S Furniss; R W Campbell
Journal:  Br Heart J       Date:  1994-04

5.  Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population.

Authors:  P Charron; O Dubourg; M Desnos; R Isnard; A Hagege; A Millaire; L Carrier; G Bonne; F Tesson; P Richard; J B Bouhour; K Schwartz; M Komajda
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

6.  Four novel KVLQT1 and four novel HERG mutations in familial long-QT syndrome.

Authors:  T Tanaka; R Nagai; H Tomoike; S Takata; K Yano; K Yabuta; N Haneda; O Nakano; A Shibata; T Sawayama; H Kasai; Y Yazaki; Y Nakamura
Journal:  Circulation       Date:  1997-02-04       Impact factor: 29.690

7.  QT-interval variability in hypertrophic cardiomyopathy patients with cardiac arrest.

Authors:  M Miorelli; G Buja; P Melacini; G Fasoli; A Nava
Journal:  Int J Cardiol       Date:  1994-06-15       Impact factor: 4.164

8.  Sustained arrhythmias in hypertrophic obstructive cardiomyopathy.

Authors:  P R Kowey; R Eisenberg; T R Engel
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

9.  The electrocardiogram in asymmetric septal hypertropy.

Authors:  R L Engler; P Smith; M LeWinter; B Gosink; A Johnson
Journal:  Chest       Date:  1979-02       Impact factor: 9.410

10.  Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients.

Authors:  B J Maron; W C Roberts; S E Epstein
Journal:  Circulation       Date:  1982-06       Impact factor: 29.690

View more
  14 in total

1.  Early remodeling of repolarizing K+ currents in the αMHC403/+ mouse model of familial hypertrophic cardiomyopathy.

Authors:  Rocco Hueneke; Adam Adenwala; Rebecca L Mellor; Jonathan G Seidman; Christine E Seidman; Jeanne M Nerbonne
Journal:  J Mol Cell Cardiol       Date:  2017-01-13       Impact factor: 5.000

2.  Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects.

Authors:  Jae-Gook Shin; Won-Ku Kang; Ji-Hong Shon; Million Arefayene; Young-Ran Yoon; Kyung-Ah Kim; Doo-Il Kim; Dong-Soo Kim; Kwang-Hyun Cho; Raymond L Woosley; David A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2006-11-10       Impact factor: 4.335

3.  A mutation in TNNC1-encoded cardiac troponin C, TNNC1-A31S, predisposes to hypertrophic cardiomyopathy and ventricular fibrillation.

Authors:  Michelle S Parvatiyar; Andrew P Landstrom; Cicero Figueiredo-Freitas; James D Potter; Michael J Ackerman; Jose Renato Pinto
Journal:  J Biol Chem       Date:  2012-07-18       Impact factor: 5.157

4.  Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy.

Authors:  Jonathan N Johnson; Camilla Grifoni; J Martijn Bos; Maha Saber-Ayad; Steve R Ommen; Stefano Nistri; Franco Cecchi; Iacopo Olivotto; Michael J Ackerman
Journal:  Eur Heart J       Date:  2011-02-22       Impact factor: 29.983

Review 5.  QTc: how long is too long?

Authors:  J N Johnson; M J Ackerman
Journal:  Br J Sports Med       Date:  2009-09       Impact factor: 13.800

6.  Impact of QT variables on clinical outcome of genotyped hypertrophic cardiomyopathy.

Authors:  Katsuharu Uchiyama; Kenshi Hayashi; Noboru Fujino; Tetsuo Konno; Yuichiro Sakamoto; Kenji Sakata; Masa-aki Kawashiri; Hidekazu Ino; Masakazu Yamagishi
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-01       Impact factor: 1.468

7.  Impaired contractile function due to decreased cardiac myosin binding protein C content in the sarcomere.

Authors:  Y Cheng; X Wan; T A McElfresh; X Chen; K S Gresham; D S Rosenbaum; M P Chandler; J E Stelzer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-10       Impact factor: 4.733

8.  ECG characteristics according to the presence of late gadolinium enhancement on cardiac MRI in hypertrophic cardiomyopathy.

Authors:  Sylvain Grall; Loïc Biere; Guillaume Clerfond; Victor Mateus; Fabrice Prunier; Alain Furber
Journal:  Open Heart       Date:  2014-08-05

Review 9.  Deciphering hypertrophic cardiomyopathy with electrocardiography.

Authors:  Thomas Gossios; Konstantinos Savvatis; Thomas Zegkos; Dimitrios Ntelios; Pavlos Rouskas; Despoina Parcharidou; Haralambos Karvounis; Georgios K Efthimiadis
Journal:  Heart Fail Rev       Date:  2021-07-21       Impact factor: 4.654

10.  Next generation sequencing-based copy number analysis reveals low prevalence of deletions and duplications in 46 genes associated with genetic cardiomyopathies.

Authors:  Ozge Ceyhan-Birsoy; Trevor J Pugh; Mark J Bowser; Elizabeth Hynes; Ashley L Frisella; Lisa M Mahanta; Matt S Lebo; Sami S Amr; Birgit H Funke
Journal:  Mol Genet Genomic Med       Date:  2015-12-16       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.